Skip to main content
OpenTrials
Completed

NCT Number: NCT01244425

Fibrin Sealant VH S/D 500 S-apr in Hepatic Resection

The purpose of the study is to compare safety and efficacy of Fibrin Sealant (FS) Vapor Heated (VH) S/D 500 s-apr with manual compression as a supportive treatment of local bleeding (i.e. oozing) in hepatic resection surgery when standard surgical techniques are insufficient.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Berlin, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Pre-Operative Inclusion Criteria:

  • Signed informed consent obtained from the subject before any study-related activities
  • Subject's age is 18 years or above
  • Subject will undergo planned, elective resection of at least 1 anatomical segment of the liver for any reason by laparotomy
  • Subject is willing and able to comply with the requirements of the protocol
  • Female subjects of childbearing potential must present with a negative serum or urine pregnancy test within 72 hours before the elective liver resection
  • Female subjects of childbearing potential must agree to employ adequate birth control measures for the time of their participation in the study

Intra-Operative Inclusion Criteria (before randomization):

  • Resection of at least 1 anatomical segment of the liver has been performed
  • Oozing from the cut surface of the liver persists after conventional resection procedure and primary control of arterial and venous bleeding by sutures, ligations, clips, vascular stapler, point electrocautery or focal radiofrequency ablation
  • Need for additional supportive hemostatic treatment to stop bleeding (i.e. diffuse oozing) of the liver resection area

Pre-Operative Exclusion Criteria:

  • Subject needs emergency liver surgery
  • Subject will undergo liver resection via laparoscopic procedure
  • Subject has known congenital coagulation disorder (e.g. hemophilia)
  • Subject has known hypersensitivity to any ingredient of the investigational medicinal product
  • Suspected inability or unwillingness of the subject to comply with trial procedures
  • If female, subject is pregnant or lactating at the time of study enrollment
  • Subject has already participated in this study (each subject can only be enrolled once)
  • Subject has participated in another clinical study involving an investigational product or investigational device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an investigational product or investigational device during the course of this study

Intra-operative Exclusion Criteria (before randomization):

  • Occurrence of any severe surgical complication that require resuscitation or deviation from the planned surgical procedure
  • Disseminated intravascular coagulopathy (DIC)
  • Application of any topical hemostatic material on the resection surface of the liver prior to application of the study treatment
  • Radiofrequency precoagulation of the liver resection surface, except focal use of radiofrequency as primary hemostatic treatment

Treatment and study plan

Fibrin Sealant (FS) VH S/D 500 s-apr

Drug

Dosage form: spray application; dosage frequency: single application

Other names: Tisseel

Manual compression

Other

Dosage form: surgical gauze swab; dosage frequency: single application

Primary outcomes

  1. Percentage of Participants With Intraoperative Hemostasis at 4 Minutes After Treatment Application

    Time frame: 4 minutes post start of treatment application

    Hemostasis defined as no visible bleeding on the liver resection surface (liver surgical site) after treatment application. Hemostasis had to be maintained until surgical closure. Time recording started with treatment application, ie, with the start of spraying Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) or with the application of manual compression.

    The following were regarded as treatment failures:

    • No hemostasis achieved at 4 minutes post treatment application (for the FS VH S/D 500 s-apr arm, the "time to hemostasis" was used; a time window of +5 seconds was acceptable for showing a success)
    • Additional hemostatic treatment (ie, hemostatics in addition to the randomized treatment) was required
    • Reapplication of FS VH S/D 500 s-apr after 4 minutes
    • Intraoperative rebleeding after the first 4 minutes of the observation period

Secondary outcomes

  1. Percentage of Participants With Intraoperative Hemostasis at 6 Minutes After Application of the Randomized Treatment

    Time frame: 6 minutes after start of treatment application

    Hemostasis defined as no visible bleeding on the liver resection surface (liver surgical site) after treatment application. Hemostasis had to be maintained until surgical closure. Time recording started with treatment application, ie, with the start of spraying Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) or with the application of manual compression.

  2. Percentage of Participants With Intraoperative Hemostasis at 8 Minutes After Application of the Randomized Treatment

    Time frame: 8 minutes after start of treatment application

    Hemostasis defined as no visible bleeding on the liver resection surface (liver surgical site) after treatment application. Hemostasis had to be maintained until surgical closure. Time recording started with treatment application, ie, with the start of spraying Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) or with the application of manual compression.

  3. Percentage of Participants With Intraoperative Hemostasis at 10 Minutes After Application of the Randomized Treatment

    Time frame: 10 minutes after start of treatment application

    Hemostasis defined as no visible bleeding on the liver resection surface (liver surgical site) after treatment application. Hemostasis had to be maintained until surgical closure. Time recording started with treatment application, ie, with the start of spraying Fibrin Sealant, Vapor Heated, Solvent/Detergent treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) or with the application of manual compression.

  4. Percentage of Participants With Intraoperative Rebleeding After Occurrence of Hemostasis

    Time frame: Intraoperative day 0

    Intraoperative rebleeding from the treated liver resection surface after occurrence of hemostasis.

  5. Percentage of Participants With Postoperative Rebleeding

    Time frame: Postoperative until discharged from surgical ward

    Rebleeding until discharged from the surgical ward, defined as any rebleeding from the treated liver resection surface requiring surgical reexploration

  6. Percentage of Participants With Transfusion Requirements Until Discharged From Surgical Ward

    Time frame: Intra- and postoperative until discharged from surgical ward

    Transfusions administered included whole blood, packed red blood cells, fresh frozen plasma, and thrombocyte concentrate.

  7. Median Total Volume of Postoperative Drainage Fluid Within 48 Hours After Surgery

    Time frame: Within 48 hours after surgery

Sponsors and collaborators

Lead sponsor

Baxter Healthcare Corporation

Industry

Collaborators

  • Baxter Innovations GmbH

Registry information

Official study title

A Randomized, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fibrin Sealant VH S/D 500 S-apr (Tisseel) for Hemostasis in Subjects Undergoing Hepatic Resection

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Nov 19, 2010
Registry last updated
Feb 20, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.